Literature DB >> 23418340

Faecal haemoglobin concentration is related to severity of colorectal neoplasia.

Jayne Digby1, Callum G Fraser, Francis A Carey, Paula J McDonald, Judith A Strachan, Robert H Diament, Margaret Balsitis, Robert J C Steele.   

Abstract

AIMS: Guaiac faecal occult blood tests are being replaced by faecal immunochemical tests (FIT). We investigated whether faecal haemoglobin concentration (f-Hb) was related to stage in progression of colorectal neoplasia, studying cancer and adenoma characteristics in an evaluation of quantitative FIT as a first-line screening test.
METHODS: We invited 66 225 individuals aged 50-74 years to provide one sample of faeces. f-Hb was measured on samples from 38 720 responders. Colonoscopy findings and pathology data were collected on the 943 with f-Hb ≥ 400 ng Hb/ml (80 µg Hb/g faeces).
RESULTS: Of the 814 participants with outcome data (median age: 63 years, range 50-75, 56.4% male), 39 had cancer, 190 high-risk adenoma (HRA, defined as ≥ 3 or any ≥ 10 mm) and 119 low-risk adenoma (LRA). 74.4% of those with cancer had f-Hb>1000 ng Hb/ml compared with 58.4% with HRA, and 44.1% with no pathology. Median f-Hb concentration was higher in those with cancer than those with no (p<0.002) or non-neoplastic (p<0.002) pathology, and those with LRA (p=0.0001). Polyp cancers had lower concentrations than more advanced stage cancers (p<0.04). Higher f-Hb was also found in those with HRA than with LRA (p<0.006), large (>10 mm) compared with small adenoma (p<0.0001), and also an adenoma displaying high-grade dysplasia compared with low-grade dysplasia (p<0.009).
CONCLUSIONS: f-Hb is related to severity of colorectal neoplastic disease. This has ramifications for the selection of the appropriate cut-off concentration adopted for bowel screening programmes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418340     DOI: 10.1136/jclinpath-2013-201445

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Fecal occult blood test and colorectal cancer: validation study with special reference to false-negative patients.

Authors:  Tomoyuki Kawada
Journal:  Dig Dis Sci       Date:  2013-07-16       Impact factor: 3.199

Review 2.  FIT testing: an overview.

Authors:  Lukejohn W Day; Taft Bhuket; James Allison
Journal:  Curr Gastroenterol Rep       Date:  2013-11

Review 3.  Faecal occult blood testing for colorectal cancer screening: the past or the future.

Authors:  Sally C Benton; Helen E Seaman; Stephen P Halloran
Journal:  Curr Gastroenterol Rep       Date:  2015-02

4.  Low Sensitivity of Fecal Immunochemical Tests (FIT) for Detection of Sessile Serrated Adenomas/Polyps Confirmed Over Clinical Setting, Geography, and FIT System.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Robert J C Steele; Callum G Fraser
Journal:  Dig Dis Sci       Date:  2019-05-18       Impact factor: 3.199

5.  Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Authors:  Chyke A Doubeni; Christopher D Jensen; Stacey A Fedewa; Virginia P Quinn; Ann G Zauber; Joanne E Schottinger; Douglas A Corley; Theodore R Levin
Journal:  J Am Board Fam Med       Date:  2016-11-12       Impact factor: 2.657

6.  Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening.

Authors:  Esmée J Grobbee; Atija Kapidzic; Anneke J van Vuuren; Monique van Leerdam; Iris Lansdorp-Vogelaar; Caspar W N Looman; Marco J Bruno; Ernst J Kuipers; Manon C W Spaander
Journal:  Am J Gastroenterol       Date:  2015-06-09       Impact factor: 10.864

7.  Low Sensitivity of Fecal Immunochemical Tests and Blood-Based Markers of DNA Hypermethylation for Detection of Sessile Serrated Adenomas/Polyps.

Authors:  Charles Cock; Shahzaib Anwar; Susan E Byrne; Rosie Meng; Susanne Pedersen; Robert J L Fraser; Graeme P Young; Erin L Symonds
Journal:  Dig Dis Sci       Date:  2019-03-05       Impact factor: 3.199

8.  The two-week rule colorectal cancer pathway: an update on recent practice, the unsustainable burden on diagnostics and the role of faecal immunochemical testing.

Authors:  W Maclean; R Singh; P Mackenzie; D White; S Benton; J Stebbing; T Rockall; I Jourdan
Journal:  Ann R Coll Surg Engl       Date:  2020-02-21       Impact factor: 1.891

9.  Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.

Authors:  Mette Kielsholm Thomsen; Lars Pedersen; Rune Erichsen; Timothy L Lash; Henrik T Sørensen; Ellen M Mikkelsen
Journal:  Br J Cancer       Date:  2022-01-20       Impact factor: 9.075

10.  The performance of three-sample qualitative immunochemical fecal test to detect colorectal adenoma and cancer in gastrointestinal outpatients: an observational study.

Authors:  Dong Wu; Han-Qing Luo; Wei-Xun Zhou; Jia-Ming Qian; Jing-Nan Li
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.